共 50 条
- [21] Effectiveness and Safety of Extended Treatment Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Venous Thromboembolism JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (06): : 397 - 403
- [23] Risk of Severe Abnormal Uterine Bleeding Associated with Rivaroxaban Compared with Apixaban, Dabigatran and Warfarin Drug Safety, 2021, 44 : 753 - 763
- [27] Apixaban versus low molecular weight heparin in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4675 - 4683